Moreover, oncogene addictive alterations involving, for example, ALK, EGFR, BRAF and ABL1 genes in non-small cell lung cancer (NSCLC), melanoma and Chronic Myeloid Leukemia (CML) represent indications for MTTs instead of chemotherapy-based regimens as first-line treatment, thus enabling significantly prolonged survival, as well as long-lasting disease control, even in metastatic patients with tumors harboring these alterations [7,8,9,10,11]. This evidence concerns the gene BRAF and chronic myelogenous leukemia, BCR-ABL1 positive.